Table 2.
Overall immunosuppression, CMV prophylaxis.
| KT following SOT (n = 97) |
Control (n = 154) |
p-value | |
|---|---|---|---|
| Induction, n (%) | 0.56 | ||
| T-cell depletion (antithymocyte globulin and alemtuzumab) | 54 (55.7) | 80 (50.9) | — |
| Basiliximab | 16 (16.5) | 1 (0.6) | 0.002 |
| Methylprednisolone | 27 (27.8) | 73 (47.4) | |
| Maintenance immunosuppression, n (%) | |||
| Tacrolimus/mycophenolate/prednisone | 80 (82.5) | 141 (91.6) | 0.04 |
| Cyclosporine/mycophenolate/prednisone | 3 (3.1) | 0 | — |
| Belatacept | 3 (3.1) | 12 (7.8) | 0.12 |
| Other | 12 (12.4) | 1 (0.6) | — |
| CMV prophylaxis, n (%) | |||
| Valganciclovir | 62 (63.9) | 86 (55.8) | 0.21 |
| Acyclovir or valacyclovir | 31 (32.0) | 63 (40.9) | 0.15 |
| None | 4 (4.1) | 5 (3.2) | 0.72 |